Boston Scientific Corporation $BSX Shares Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 5.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,589,385 shares of the medical equipment provider’s stock after buying an additional 617,515 shares during the period. Janus Henderson Group PLC’s holdings in Boston Scientific were worth $1,200,404,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth approximately $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the 4th quarter worth approximately $26,000. Colonial Trust Co SC lifted its position in Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares in the last quarter. Bangor Savings Bank lifted its position in Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares in the last quarter. Finally, Board of the Pension Protection Fund acquired a new position in Boston Scientific during the 4th quarter worth approximately $29,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward J. Ludwig purchased 3,580 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders acquired 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research analyst reports. Mizuho lowered their price target on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Needham & Company LLC reiterated a “buy” rating and issued a $77.00 price target on shares of Boston Scientific in a report on Monday, May 18th. Weiss Ratings downgraded Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $65.00 price target on shares of Boston Scientific in a report on Friday, June 12th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $85.08.

Boston Scientific Price Performance

Shares of BSX opened at $44.86 on Thursday. The company has a market cap of $66.68 billion, a P/E ratio of 18.77, a PEG ratio of 0.90 and a beta of 0.56. The stock has a fifty day moving average price of $55.38 and a 200 day moving average price of $73.62. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a 12 month low of $44.79 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the prior year, the business posted $0.75 earnings per share. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its board has initiated a stock buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.